SCHEMBL3528608

SCHEMBL3528608

O=C(c1nc(C2CCC(C(F)(F)F)CC2)sc1COc1ccc(-c2noc(=O)[nH]2)c(F)c1)N1CCC(C(F)(F)F)CC1

nearest known ligand 0.35

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 2/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 1/20 0.35
SPR P35270 8/20 0.34
F11 P03951 1/20 0.34
HRH3 Q9Y5N1 1/20 0.33
HRH1 P35367 1/20 0.33
CCR3 P51677 1/20 0.33
DPP4 P27487 1/20 0.33
KCNH2 Q12809 1/20 0.33
DPP7 Q9UHL4 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
RORC P51449 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13343424 1.00 AGTR1 (0.35) AGTR1NPC1RAB9ASPRF11
SCHEMBL14541662 0.85 AGTR1 (0.33) AGTR1F11HRH3
SCHEMBL3529129 0.85 AGTR1 (0.33) AGTR1F11HRH3
SCHEMBL13343416 0.85 PPARD (0.35) AGTR1ALDH1A1
SCHEMBL3529734 0.85 PPARD (0.35) AGTR1ALDH1A1
SCHEMBL13343426 0.81 PDE4A (0.36) NPC1RAB9AALDH1A1
SCHEMBL3529357 0.77 AGTR1 (0.34) AGTR1HRH3KCNH2ALDH1A1LMNA
SCHEMBL13343397 0.77 AGTR1 (0.34) AGTR1HRH3KCNH2ALDH1A1LMNA
SCHEMBL3524448 0.77 AGTR1 (0.34) AGTR1ALDH1A1LMNA
SCHEMBL13343385 0.77 AGTR1 (0.34) AGTR1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1931337-B1 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2013-10-23 EP disclosed
US-7709481-B2 Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals SANOFI-AVENTIS (FR) 2010-05-04 US disclosed
US-20080261979-A1 Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals SANOFI-AVENTIS (FR) 2008-10-23 US disclosed
EP-1931337-A2 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2008-06-18 EP disclosed
WO-2007039177-A2 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (DE) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261979-A1 Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals PPARD, PPARA, PPARG AGTR1 151/4885NPC1 1228/4885RAB9A 3915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.